No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
002317 Guangdong Zhongsheng Pharmaceutical
- 11.98
- -0.15-1.24%
Market Closed May 12 15:00 CST
10.20BMarket Cap-38.03P/E (TTM)
12.09High11.82Low295.11KlotVolume11.90Open12.13Pre Close352.29MTurnover3.88%Turnover RatioLossP/E (Static)851.56MShares14.9652wk High2.55P/B9.12BFloat Cap9.8552wk Low13.34Limit Up761.62MShs Float40.90Historical High10.92Limit Down2.23%Amplitude2.52Historical Low0.20Dividend TTM11.94Avg Price161.45KlotAsk1.67%Div YieldTTM100Lot Size126.05KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Guangdong Zhongsheng Pharmaceutical: The core patent of the RAY1225 project held by the subsidiary has been authorized in Japan.
Guangdong Zhongsheng Pharmaceutical (002317): In 2025, fresh start; suggest paying attention to the progress of the innovation pipeline.
Investment highlights: Event: The company released the 2024 annual report and the first quarter report for 2025. In 2024: Achieved revenue of 2.47 billion yuan, a year-on-year decrease of 5.5%, with a net income attributable to shareholders of -0.3 billion yuan, a year-on-year decrease of 213.6%, excluding
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Guangdong Zhongsheng Pharmaceutical's RAY1225 Injection, a class of Innovative Drugs, has obtained top-line analysis data results from its Phase II clinical trial.
On May 6, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced that its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (referred to as "Zhongsheng Ruichuang"), has independently developed an innovative polypeptide drug, RAY1225 injection, which recently obtained topline analysis data from the dose expansion group of two Phase II clinical trials focused on weight loss and blood sugar reduction. Preliminary results indicate that RAY1225 injection at doses of 3-9 mg showed positive efficacy and good safety in adult participants with obesity/overweight and participants with Type 2 diabetes in China, with ideal trial results achieving the expected objectives.
Guangdong Zhongsheng Pharmaceutical (002317): Impairment provisions in 2024 lead to losses, while the progress of Innovative Drugs in 2025 is promising.
Event: The company released the annual report for 2024 and the first quarter report for 2025. In 2024, the company achieved a revenue of 2.467 billion yuan, a decrease of 5.48% year-on-year; achieved a net income of -0.299 billion yuan, year-on-year.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) reported a net income of 82.6118 million yuan in the first quarter, an increase of 61.06% year-on-year.
On April 26, Gelonghui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) released its quarterly report, achieving a total operating income of 0.634 billion yuan in the first quarter of 2025, a decrease of 1.07% year-on-year; the net income attributable to shareholders of the parent company was 82.6118 million yuan, an increase of 61.06% year-on-year; the EPS was 0.1 yuan.
Zhongsheng Pharmaceutical: First Quarter Report 2025
Market Insights
Tariff Storm Hits: Hedge with ETFs? Tariff Storm Hits: Hedge with ETFs?
The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.
Unlock Now
Discussing
中美會談取得重要進展！市場會否迎來狂歡？
市場重磅利好消息不斷！5月11日，中美經貿中方牽頭人、國務院副總理何立峰表示中美經貿高層會談取得實質性進展。5月12日下午，中方公佈中美日內瓦經貿會談聯合聲明。聲明公佈後，港股瞬間拉漲，恒生指數一度漲超3%，恒生科技指數一度漲超5%。中美經貿會談取得實質性進展，關稅鬧劇迎來驚喜轉
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th